Performance Period: 4/1/2021 to 5/31/2023
Chimeric antigen receptors (CARs) T-cell therapy has become an important approach for cancer treatment. This project aims develop a novel perfusion-based, beads-free, bioreactor system as a new platform for CAR T cell manufacturing with the intent to simplify the manufacturing process and form the foundation for achieving full automation. The system is designed to facilitate scaling the manufacturing of CAR T cells for different uses, which can then be applied across a broad array of T-cell based applications. The approach aims to reduce development costs, shorten timelines, and bring direct benefit to patients.
The development of this novel perfusion-based system would facilitate scaling the manufacturing of CAR T cells for different users.
Login to the NIIMBL member portal to access more, including:
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
Southwest Research Institute
Genentech, Inc.
Merck Sharp & Dohme LLC
University of Pennsylvania
Xcellerate Biotech Inc.
